The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these indications. While products indicated for obesity do not currently have a large market presence, there are a large number of these products in the pipeline, with the majority in early stages of development.
The combined therapy area of diabetes and obesity presents a strong pipeline, accounting for a large proportion of the overall metabolic disorders therapy area. The majority of products are small molecules and biologics, which reflects the overall pharmacotherapeutic market trend.
An increasing pipeline presence for obesity-indicated products and overwhelming global media interest highlight the relevance of this indication and its future potential global revenues. However, the number of pharmacotherapeutic products for obesity is dwarfed by diabetes-indicated products. Given the status of obesity as a risk factor for T2DM, it is likely that the T2DM pipeline will continue to grow with the rising obesity incidence.
Key topics covered in report
Diabetes and Obesity Drug Development Size
Diabetes and Obesity Drug Development Share
Diabetes and Obesity Drug Development Trends
Diabetes and Obesity Drug Development Growth
Diabetes and Obesity Drug Development Outlook
Diabetes and Obesity Drug Development Analysis
Diabetes and Obesity Drug Development Research
Diabetes and Obesity Drug Development Revenue
Diabetes and Obesity Drug Development Research Report
For more coverage click on the link below:
Ankur Gupta, Head Marketing & Communications